CytoDyn Inc.

CYDY · OTC · SIC 2834: Pharmaceutical Preparations
356
SEC Filings

Business Summary

CytoDyn Inc. is a clinical-stage biotechnology company focused on the development and potential commercialization of leronlimab (PRO 140), a humanized monoclonal antibody targeting the CCR5 receptor. The company is studying leronlimab for solid-tumor oncology indications, including microsatellite stable metastatic colorectal cancer and metastatic Triple-Negative Breast Cancer, and is also researching a long-acting version of leronlimab.

Next Earnings

Q2 FY2026 — expected 2026-07-08

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionCYDYdiscussed_in_filing Artificial Intelligence
topic_mentionCYDYdiscussed_in_filing Cybersecurity
topic_mentionCYDYdiscussed_in_filing Trusted Computing
topic_mentionCYDYdiscussed_in_filing Blockchain & Crypto
topic_mentionCYDYdiscussed_in_filing Regulation
topic_mentionCYDYdiscussed_in_filing Healthcare & Bio
topic_mentionCYDYdiscussed_in_filing Sovereign & Government
topic_mentionCYDYdiscussed_in_filing Artificial Intelligence
topic_mentionCYDYdiscussed_in_filing Cybersecurity
topic_mentionCYDYdiscussed_in_filing Trusted Computing
topic_mentionCYDYdiscussed_in_filing Blockchain & Crypto
topic_mentionCYDYdiscussed_in_filing Regulation
topic_mentionCYDYdiscussed_in_filing Healthcare & Bio
topic_mentionCYDYdiscussed_in_filing Sovereign & Government
topic_mentionCYDYdiscussed_in_filing Artificial Intelligence
topic_mentionCYDYdiscussed_in_filing Cybersecurity
topic_mentionCYDYdiscussed_in_filing Trusted Computing
topic_mentionCYDYdiscussed_in_filing Blockchain & Crypto
topic_mentionCYDYdiscussed_in_filing Regulation
topic_mentionCYDYdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2025-07-252025-05-310001558370-25-009617EDGAR54K words
2024-08-152024-05-310001558370-24-012328EDGAR—
2023-09-142023-05-310001558370-23-015718EDGAR—
2022-08-152022-05-310001558370-22-013680EDGAR—
2021-07-302021-05-310001558370-21-009730EDGAR—
2020-08-142020-05-310001193125-20-220598EDGAR—
2019-08-142019-05-310001193125-19-221300EDGAR—
2018-07-272018-05-310001193125-18-229738EDGAR—
2017-07-202017-05-310001193125-17-231500EDGAR—
2016-07-192016-05-310001193125-16-651305EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-01-092025-11-300001104659-26-002335EDGAR19K words
2025-10-102025-08-310001104659-25-098552EDGAR—
2025-04-142025-02-280001558370-25-004774EDGAR—
2025-01-142024-11-300001558370-25-000207EDGAR—
2024-10-152024-08-310001558370-24-013320EDGAR—
2024-04-152024-02-290001558370-24-005134EDGAR—
2024-01-162023-11-300001558370-24-000305EDGAR—
2023-10-232023-08-310001558370-23-016632EDGAR—
2023-04-102023-02-280001558370-23-005695EDGAR—
2023-01-092022-11-300001558370-23-000163EDGAR—
2022-10-112022-08-310001558370-22-014943EDGAR—
2022-04-112022-02-280001558370-22-005291EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-240001104659-26-033943EDGAR1K words
2026-03-050001104659-26-023856EDGAR—
2025-12-010001104659-25-117154EDGAR—
2025-11-210001104659-25-115056EDGAR—
2025-11-030001104659-25-105306EDGAR—
2025-05-160001558370-25-007954EDGAR—
2025-05-060001558370-25-006531EDGAR—
2024-11-220001558370-24-015918EDGAR—
2024-07-090001558370-24-009701EDGAR—
2024-06-280001558370-24-009629EDGAR—

356 total filings indexed. 324 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

solid-tumor-oncology metastatic-colorectal-cancer metastatic-triple-negative-breast-cancer clinical-stage-biotechnology

Company Identity

CIK0001175680
TickerCYDY
ExchangeOTC
SIC2834: Pharmaceutical Preparations
IncorporatedDE
HeadquartersVancouver, Washington

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 97c8e129382126ba7606869726d0fd2571a69991a0f3b104d85a8e094cdc6778
parent: 3f1254f23bed129cb93ad00467442d5638c5b33984db70dcbb13046e64377fb4
content hash: faa051a2fef7e1cc8bb60a4fdebe3707fdcb0c7c4aa24e63235549b5a114fe89
signed: 2026-04-13T04:44:35.758Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf